Arsenic Trioxide in Treating Patients With Relapsed or Refractory Lymphoma or Leukemia

Stopped early · Not applicable

Conditions studied: Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Prolymphocytic Leukemia, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Splenic Marginal Zone Lymphoma, Waldenström Macroglobulinemia

In brief

Phase II trial to study the effectiveness of arsenic trioxide in treating patients who have relapsed or refractory lymphoma or leukemia. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die

Key facts

Study ID: NCT00005786
Run by: National Cancer Institute (NCI)
People needed: 25
Starts: 2001-01-01
Last updated by the study team: 2013-02-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Patients must have a diagnosis of relapsed or refractory low-grade lymphoma
Patients must have disease that has relapsed from or is refractory to standard cytotoxic therapy; patients must have received at least one standard cytotoxic drug regimen; there is no limit on the number of prior therapies, including high dose chemotherapy regimens, provided the patient has recovered from prior toxicities; relapsed disease is defined as the development of lymphadenopathy, splenomegaly, malignant lymphocytosis greater than 5,000, or infiltration of the bone marrow with malignant lymphocytes in a patient who had previously achieved a response of at least six months in duration; refractory disease is defined as never achieving a PR or a CR or PR that is less than six months in duration; prior total body irradiation is not allowed; radiation to individual site is permitted, and is not included as a regimen
Serum creatinine =< 2.0 mg/dl
Total bilirubin =< 2.0 mg/dl
Serum SGOT, SGPT =< 2.5 times the upper limit of institutional normal
Patients who are female and have childbearing potential must have a negative pregnancy test; all patients who are engaging in sexual intercourse that may result in a pregnancy must use appropriate contraception while receiving treatment on this protocol
Patients must have sufficient mental capacity to understand the explanation of the study and to give his or her informed signed consent
Patients must display Karnofsky performance status of 60% or greater
Patients should have a life expectancy of > 12 weeks so as to permit adequate follow-up of toxicity
Patients must have recovered from the toxicity of recent therapy prior to enrollment in this study
Absolute neutrophil count > 1500/uL, unless cytopenias are the result of bone marrow infiltration by lymphoma; permission of the protocol PI is required in this situation
Platelet count > 75,000/uL, unless cytopenias are the result of bone marrow infiltration by lymphoma; permission of the protocol PI is required in this situation; patients with thrombocytopenia secondary to active ITP or anemia secondary to an active autoimmune hemolytic anemia at the time of evaluation are excluded

You may not qualify if…

Pregnant or lactating women; arsenic compounds could be transferred to the fetus or child with resultant harm
Concurrent treatment with cytotoxic chemotherapy, radiation or investigational agents; this exclusion does not include concurrent glucocorticoids fro brief durations; patients must have recovered from the toxicity of prior therapy prior to enrollment in this study
Active serious infections not controlled by antibiotics
Inability to comply with the treatment protocol or follow-up testing
Patients with HIV infection; there are currently insufficient data to support the safety of administering arsenic compounds in combination with anti-retroviral drugs
Patients with active viral or autoimmune hepatitis
Patients with history of cardiac arrhythmia, heart block, or myocardial infarction within the past 6 months
Patients with known CNS disease
Patients requiring amphotericin B therapy
Patients with significant peripheral neuropathy (>= grade 3), regardless of cause

Where it is running

Mount Sinai Medical Center — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.